thanks for posting that extra info. i must admit to being...

thanks for posting that extra info. i must admit to being totally out of my depth with the science behind Cpn10. The risk profile for this drug, despite it's huge potential, I would imagine would make it a tough call for the decision makers at the pharma companies interested to put their name to further investment / development.

I wonder what the most likely outcome will be with Ferghana Partners involvement in the pursuit of a cornerstone investment / partnership / outright sale?

The company clearly does need to deliver on one of these fronts in the short to medium term to avoid further dilutive and damaging capital raises. If there is any meaningful interest from pharma companies / investors out there, it's conceivable that a deal could be finalised in the next month or two.

I wonder if we will see any signs of a pending deal with increased trading activity?

Fingers crossed for a good outcome, especially for the long term holders who I'm sure have endured a lot of disappointment so far with this stock.